Salud financiera de hoja de balance de Grifols

Salud financiera controles de criterios 2/6

Grifols tiene un patrimonio de accionistas total de €8.0B y una deuda total de €9.5B, lo que sitúa su ratio deuda-patrimonio en 119.6%. Sus activos y pasivos totales son €21.4B y €13.5B respectivamente. El BAIT de Grifols es de €735.7M, por lo que su ratio de cobertura de intereses es de 1.9. Tiene efectivo e inversiones a corto plazo que ascienden a €646.0M.

Información clave

140.3%

Ratio deuda-patrimonio

€11.40b

Deuda

Ratio de cobertura de intereses	2.2x
Efectivo	€448.55m
Patrimonio	€8.12b
Total pasivo	€13.83b
Activos totales	€21.95b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€6.5B) de G0FB superan a sus pasivos a corto plazo (€2.3B).

Pasivo a largo plazo: Los activos a corto plazo (€6.5B) de G0FB no cubren sus pasivos a largo plazo (€11.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de G0FB (111.5%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de G0FB ha pasado de 133.8% a 119.6% en los últimos 5 años.

Cobertura de la deuda: La deuda de G0FB no está bien cubierta por el flujo de caja operativo (2.2%).

Cobertura de intereses: Los pagos de intereses de la deuda de G0FB no están bien cubiertos por el BAIT (1.9x cobertura).

Salud financiera de hoja de balance de Grifols

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Grifols Begins Clinical Trial of A New Treatment That Would Provide Immediate Immunity Against Covid-19

Grifols, S.A. Announces Board Appointments

Grifols, S.A. (BME:GRF) completed the acquisition of remaining 52.4% stake in Alkahest, Inc.

Grifols, S.A. Executes Binding Master Joint Venture Agreement with National Service Projects Organization

B. Braun Melsungen AG and Grifols Forms Strategic Alliance to Offer Integrated Solutions for Safe Automated Drug Preparation and Administration

Grifols, S.A. (BME:GRF) acquired remaining 49% stake in Goetech LLC for $60.2 million.

Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with Covid-19

Grifols, S.A. (BME:GRF) agreed to acquire 53.4% stake in Green Cross Biotherapeutics Inc. from Green Cross North America Inc. for approximately KRW 190 billion.

Grifols, S.A. to Report Q3, 2020 Results on Nov 05, 2020

Grifols, S.A. (BME:GRF) completed the acquisition of Plasma Fractionation Facility in Montreal and Plasma Collection Centers in US from Green Cross Corporation (KOSE:A006280).

Grifols, S.A. (BME:GRF) agreed to acquire remaining 52.4% stake in Alkahest, Inc. for approximately $150 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera